LUND, SWEDEN, Oct. 27, 2023 /PRNewswire/ — Immunovia AB (publ), reg. no. 556730-4299 (the “Company“), hereby gives notice that an extraordinary general meeting will take place on Tuesday 21st November 2023 at 10.00 in the Company’s offices at Medicon Village, Scheeletorget 1, Lund. Registration to the extraordinary general meeting starts at 09:45. Notice/Right to participate at … Read more
LUND, Sweden, July 12, 2023 /PRNewswire/ — Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the … Read more
LUND, Sweden, June 9, 2023 /PRNewswire/ — Immunovia AB (Nasdaq: IMMNOV) announces today that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK. His total holding now amounts to 350 000 shares and 100 000 warrants in Immunovia. About Immunovia Immunovia is a diagnostic company with the vision to revolutionize … Read more
LUND, Sweden, June 9, 2023 /PRNewswire/ — Immunovia AB (Nasdaq: IMMNOV) announces today that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK. His total holding now amounts to 350 000 shares and 100 000 warrants in Immunovia. About Immunovia Immunovia is a diagnostic company with the vision to revolutionize … Read more
LUND, Sweden, May 31, 2023 /PRNewswire/ — The number of shares and votes in Immunovia AB (publ) (“Immunovia”) have changed as a result of new shares being issued in the rights issue resolved by the board of directors on 20 February 2023, subject to approval from the extraordinary general meeting on 16 March 2023. Through the … Read more
LUND, Sweden, May 26, 2023 /PRNewswire/ — On 26th May 2023, an Annual General Meeting (AGM) was held in Immunovia AB (publ), 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund. Below is a summary of the resolutions made at the AGM. Allocation of the company’s available profits and discharge from liability The AGM resolved … Read more
LUND, Sweden, May 26, 2023 /PRNewswire/ — On 26th May 2023, an Annual General Meeting (AGM) was held in Immunovia AB (publ), 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund. Below is a summary of the resolutions made at the AGM. Allocation of the company’s available profits and discharge from liability The AGM resolved … Read more
LUND, Sweden, May 23, 2023 /PRNewswire/ — January-March 2023 Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60). Net earnings were MSEK -51.7 (-44.1) and earnings per share before and after dilution were SEK -2.28 (-1.95). Cash Flow from operating activities were MSEK -39.7 (-46.1). … Read more
LUND, Sweden, May 22, 2023 /PRNewswire/ — Immunovia AB (publ) (“Immunovia“) published the notice to the Annual General Meeting 2023 on 25 April 2023 together with the Nomination Committee’s motivated statement which included the Nomination Committee’s proposals for board members. The Nomination Committee has now been informed that Helge Lubenow, Sven Andréasson and Vanessa Rollings … Read more
LUND, Sweden, May 17, 2023 /PRNewswire/ — Immunovia will publish its first quarter 2023 results on May 23, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding, CEO … Read more